The applicant has optimized the Restriction Landmark Genomic Scanning (RLGS) method for the detection of genetic and epigenetic alterations in human cancers. RLGS is a two-dimensional gel electrophoresis technique, in which up to 2,000 end-labeled NotI restriction sites are displayed in a single gel. Rapid cloning of RLGS spots is accomplished with the help of an arrayed NotI-EcoRV library. The use of methylation sensitive restriction enzymes (RLGS-M) allows scanning for altered DNA methylation pattern. It is well established that inactivation of tumor suppressor genes can lead to neoplastic transformation. The mechanisms of inactivation are incompletely understood, but include DNA methylation of the gene's promoter sequence. This has important therapeutic implications, because certain drugs used successfully to treat cancer result in demethylation of DNA. Here, the applicant and his colleagues propose to utilize the unique ability of RLGS-M to scan the genomes for promoter methylation in acute myeloid leukemias (AML). They hypothesize that DNA methylation promotes the survival of AML cells that resist intensive treatment. In preliminary studies, they have used RLGS-M to identify WIT1, a gene methylated in relapsed AML but not methylated at diagnosis or in normal tissue. The applicant and his colleagues propose four specific aims: I) to screen additional cases of AML with normal karyotype for evidence of DNA methylation; II) to clone those loci which are methylated at high frequencies; III) to correlate the findings with clinical outcome by testing a larger set of AML with methylation-sensitive-PCR; and IV) to clone novel genes linked to the methylated sites. The applicant hopes that the work will form the basis for therapeutic trials to demethylate such genes in the hope of improving the rate of cure with intensive treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA080912-02
Application #
6174029
Study Section
Pathology B Study Section (PTHB)
Program Officer
Lively, Tracy (LUGO)
Project Start
1999-05-01
Project End
2001-04-30
Budget Start
2000-05-01
Budget End
2001-04-30
Support Year
2
Fiscal Year
2000
Total Cost
$109,500
Indirect Cost
Name
Ohio State University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Fruhwald, Michael C; Plass, Christoph (2002) Global and gene-specific methylation patterns in cancer: aspects of tumor biology and clinical potential. Mol Genet Metab 75:1-16
Plass, Christoph; Soloway, Paul D (2002) DNA methylation, imprinting and cancer. Eur J Hum Genet 10:6-16
Smiraglia, D J; Rush, L J; Fruhwald, M C et al. (2001) Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet 10:1413-9
Rush, L J; Dai, Z; Smiraglia, D J et al. (2001) Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. Blood 97:3226-33
Costello, J F; Plass, C (2001) Methylation matters. J Med Genet 38:285-303
Costello, J F; Fruhwald, M C; Smiraglia, D J et al. (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132-8
Smiraglia, D J; Fruhwald, M C; Costello, J F et al. (1999) A new tool for the rapid cloning of amplified and hypermethylated human DNA sequences from restriction landmark genome scanning gels. Genomics 58:254-62